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Abstract  
 
Cancer can be defined as an unbalance between cell proliferation and apoptosis. 
The PI3K/AKT signalling pathway is one of the most mutated pathways in cancer and is 
involved in cell growth and survival. The transcription factor FOXO3a is a critical 
effector of this pathway and its inactivation by AKT prevents the expression of genes 
involved in cell cycle arrest and apoptosis. The TRIB2 protein was found to be a repressor 
of FOXO3a, and over expressed in many types of cancer. Importantly, TRIB2confers 
resistance to PI3K inhibitors which are being tested in clinical trials.  
This work shows that following PI3K inhibitor treatment, there is an increase of the 
TRIB2 protein levels by reducing proteasomal degradation. Furthermore, the TRIB2 
COP1 binding domain is critical for AKT activation and subsequent FOXO repression.  
Altogether, our results provide insight into the mechanism underlying TRIB2 
mediated tumorigenesis and drug resistance implicating the binding and activation of 
AKT and suggests a role of TRIB2 in acquired resistance against PI3K inhibitors. 
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Resumo  
O Cancro é caracterizado por uma proliferação celular descontrolada oriunda de 
danos e/ou mutações no ADN. Estas alterações surgem na grande maioria de erros durante 
o processo de replicação, falhas nos mecanismos de reparação, exposição a fatores 
ambientais ou a agentes cancerígenas. Existem seis alterações essências que uma célula 
normal submete-se na transformação em célula tumoral: evasão a supressores externos de 
crescimento celular, sinalização constitutiva de proliferação, evasão à apoptose (morte 
celular programada), capacidade própria de induzir angiogênese (produção de novos 
vasos sanguíneos), potencial replicativo ilimitado que torna a célula “imortal” e 
capacidade metastática de invadir outro tecidos. Recentemente, mais quatro 
características foram adicionadas, sendo elas: evasão ao sistema imunitário, instabilidade 
genómica, desregulação do balanço energético celular e capacidade de inflamação 
indutora de tumores. 
O Cancro é uma das maiores ameaças á saúde humana a nível mundial. Dentro dos 
tipos de cancro mais preocupantes está o cancro de pele, mais especificamente o 
Melanoma. Esta forma agressiva de cancro de pele desenvolve-se a partir de melanócitos, 
células especializadas na produção de melanina. Embora este tipo de cancro de pele seja 
uma minoria (menos de 5% dos casos totais), é um dos mais letais, sendo responsável por 
aproximadamente 80% de todas as mortes devido a cancro de pele. Com a sua incidência 
dentro da faixa etária dos 30 aos 60 anos, em particular em pessoas de pele mais clara. O 
facto de cada vez mais surgirem casos de jovens entre os 25-29 anos é alarmante. O 
aumento anual da sua incidência têm-se refletido numa subida na taxa de mortalidade 
associada a este tipo de cancro. 
Esta doença oncológica é extremamente agressiva e heterogénea, com vários 
subtipos histológicos e perfis mutacionais. Adere-se o problema que os tratamentos 
convencionais são pouco eficazes e as drogas mais recentes que conseguem ter resultados 
tornam-se ineficazes devido aos tumores adquirirem resistência num espaço de meses. A 
totalidade destes factos confere aos pacientes um prognóstico pessimista. 
Devido a estes factos, a investigação científica têm-se empenhado em perceber os 
mecanismos moleculares afetados por esta patologia e em como esse conhecimento pode 
auxiliar na produção de tratamentos mais eficazes. É o caso da via de sinalização de PI3K, 
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que se verificou ser desregulada em Melanoma, que levou ao desenvolvimento de 
inibidores capazes de reverter esta alteração, como BEZ235. 
A via de sinalização de PI3K/AKT é importante na regulação de diversos processos 
biológicos, tais como proliferação celular, metabolismo, crescimento celular e apoptose. 
Esta via é ativada pela ligação de fatores de crescimento ao recetor de tirosina quinase na 
membrana celular. Este recetor, através de fosforilação, ativa PI3K que converte fosfatidil 
inositol 4,5-difosfato (PIP2) em fosfatidil inositol 3,4,5-trifosfato (PIP3). Este processo é 
regulado negativamente por PTEN, uma fosfatase que tem como substrato PIP3. O 
aumento de PIP3 recruta AKT para a membrana, fazendo com que seja ativado por outras 
quinases através de fosforilação dos seus resíduos Treonina 308 e Serina 473. Após esta 
ativação, AKT fosforila várias moléculas alvo no citoplasma e no núcleo, como por 
exemplo p27, BAD, GSK3, MDM2 e FOXO. 
Os fatores FOXO são uma família de fatores de transcrição que funcionam como 
ativadores ou repressores, dependendo dos seus cofatores a quando da sua ligação ao 
ADN. Esta família é fundamental em processos como apoptose, metabolismo, 
diferenciação celular, inflamação, proliferação e resposta ao stress oxidativo. 
O fator de transcrição p53 é responsável pela regulação de vários genes envolvidos 
em apoptose, paragem do ciclo celular, senescência, metabolismo e autofagia. Devido a 
estas funções, é considerado o “guardião do genoma” e o seu papel contra o 
desenvolvimento tumoral é bem conhecido. O p53 é regulado por MDM2, uma ubiquitina 
ligase responsável pela sua ubiquitinação e consequente degradação proteossómica. Na 
verdade, p53 e MDM2 exercem um feedback loop, sendo que o gene de MDM2 é um dos 
alvos de p53, mantendo assim os níveis de p53 constantes dentro da célula.       
O TRIB2 é um gene que tem sido associado ao desenvolvimento de cancro e foi 
recentemente considerado um biomarcador para o prognóstico e para a progressão de 
Melanoma. A sua sobre expressão proteica afeta negativamente os tratamentos 
convencionais a este tipo de cancro. Também está implicado na regulação negativa de 
FOXO. Dado que este fator de transcrição é uma das vias que as drogas usadas nas 
terapias utilizam para exercer efeitos citotóxicos e/ou citostáticos sobre as células 
tumorais, a regulação que TRIB2 exerce sobre FOXO evidencia o seu papel na resistência 
a quimioterapêuticos (como o clássico DTIC ou o inibidor BEZ235). 
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Pesquisas antecedentes feitas pelo nosso grupo laboratorial demonstraram que o 
uso de inibidores de PI3K estabilizam os níveis proteicos de TRIB2 e que existe uma 
interação entre TRIB2 e AKT. Neste trabalho, procuramos perceber como TRIB2 é 
regulado dentro da célula e como interage com a via de sinalização PI3K/AKT. 
Durante a nossa investigação constatámos que os níveis proteicos de TRIB2 eram 
estabilizados na presença de inibidores de PI3K devido a um decréscimo da sua 
degradação proteossómica. Isto implica que a via de sinalização de PI3K está envolvida 
na modificação translacional de TRIB2 necessária para a sua degradação. Os mecanismos 
envolvidos nesta degradação e os seus participantes permanecem desconhecidos. No 
entanto, estes resultados conseguem demonstrar como TRIB2 influencia a resistência a 
drogas, como verificado nos casos de Melanoma. 
Também observámos que a interação entre AKT e TRIB2 é feita através do domínio 
de ligação a COP1 existente na zona C-terminal de TRIB2. Verificámos que esta 
interação implica um decréscimo na expressão de genes envolvidos em apoptose e em 
paragem do ciclo celular como FasLG e p27, respetivamente. Estes resultados evidenciam 
que a interação entre AKT e TRIB2 está relacionada com a regulação negativa de FOXO. 
Como confirmação, avaliámos os níveis proteicos de p27 e BIM, genes regulados por os 
fatores FOXO. Estes resultados implicam que TRIB2 funciona como uma proteína 
scaffold ou adaptadora, que permite a ativação de AKT no resíduo Serina 473.  
Em conjunto, estes resultados demonstram como a regulação de TRIB2 e a sua 
interação com AKT auxiliam as células tumorais a adquirirem resistência a 
quimioterapêuticos, não só no tratamento de Melanoma mas em outras patologias 
oncológicas onde a via de sinalização de PI3K/AKT esteja alterada. 
 
Palavras-chave: Cancro, Melanoma, TRIB2, FOXO3a, via de sinalização de 
PI3K, MDM2 
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1. Introduction 
1.1- Cancer 
Cancer is characterized by unregulated cell proliferation typically arising as a result 
of DNA damage/mutations. Typically this occurs by environmental factors such as 
ultraviolet radiation, diet, pollution or viral infection. However, these  can also occur 
through punctual mutations, errors in replication and/or by failings in the cell’s DNA 
repair machinery (1).  
The hallmarks of cancer describe the necessary, minimum genetic alterations that a 
normal cell must undergo to become transformed (1). These include the evasion of growth 
suppressors, constitutive proliferative signalling, the avoidance of apoptosis 
(programmed cell death), the capacity to induce angiogenesis (formation of new blood 
vessels), replicative immortality and activating invasion/metastasis (1). These six were 
the original principal hallmarks 
however since these were described, 
four additional hallmarks have been 
incorporated. These are  avoiding 
immune destruction, genome 
instability, deregulating cellular 
energetics and tumour-promoting 
inflammation (1). 
Cancer in general is a major 
health issue world-wide. According 
to the World Health Organization 
(WHO), 8.2 million people died of 
cancer world-wide in 2012 and 30 % 
of cancer cases can be prevented. 
With the increase of life expectancy, 
the likelihood of developing any 
type of tumour also increases (Figure 1.1). Combined with an improvement in detection 
technics, there was a rise of cancer incidence (2). In compensation, the advances in 
treatments have allowed to lower the mortality rate.     
The tumorigenesis process can be influenced by many factors such as genetic 
susceptibility and lifestyle, leading to a heterogeneity of tumours amongst patients. Even 
Figure 1.1.1 - Trends in cancer incidence and mortality 
rates. Trends for both sexes in the United States from 1975 
to 2011. Adapted from Siegel et al.; Cancer Statistics, 2015; 
CA CANCER J CLIN 2015;65:5–29 
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the contribution of a person’s diet to the development of cancer is not yet fully 
understood. To add to the problem, there are many examples of tumour resistance to most 
treatments. 
The first step in the standard treatment for a majority of cancers is surgery (if the 
tumour is located within an operable region). Assuming that the tumour can be removed, 
the patient will be subjected to adjuvant treatment that includes radiotherapy and/or 
chemotherapy. Radiotherapy consists of using radiation to damage the DNA and kill any 
actively dividing cells (including both normal and tumour cells). Chemotherapy uses 
drugs to achieve the same objective. Chemotherapy must take in consideration many 
factors such as type of cancer, its extent and localization. Both types of treatment are 
given in cycles to allow the patients to recover from the inherent toxicities of these 
therapeutic approaches. 
The greatest problems in the treatment of cancer are late diagnosis, poor patient 
response to treatment and the re-emergence of resistant cancer cells following a variable 
remission period. Many patients are treated with a combination of chemotherapeutics and 
still have little to no objective response to therapy. Furthermore, the patients that do have 
a measurable response typically acquire resistance to treatments in a short period of time. 
This delay between remission and the emergence of resistant cancer cells is highly 
variable and is dependent on the type of cancer. Consequently there has been a great focus 
in developing new therapeutic agents and modalities. One of this new treatments is 
immunotherapy. This modality is based upon the interplay between the tumours and the 
microenvironment where they are located. Immunotherapy can be used to increase the 
patients’ immune system to recognise and subsequently eliminate the cancer cells (3). As 
cancers harbour many genetic mutations, a number of some tumours have proteins that 
can be recognize as foreign antigens (4). While promising, most tumours are identified as 
“self” by the host and thus are able to escape immune system detection. The use of 
targeted molecules capable of inducing an antitumour immune response can help gain a 
chemotherapeutic effect, by “boosting” the detection capabilities of the immune system 
(3). 
Another approach to cancer treatment is targeted therapy. By investigating the 
aberrant molecular pathways in cancer, many therapeutic targets have been identified. 
These potential targets must be as exclusive to the tumour cells as possible to avoid 
indirectly affecting any normal cells exposed to the therapeutic. Many such 
chemotherapeutics have already been developed and have proven to be considerably more 
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effective than the previous non-specific drugs. A prime example is Gleevec© (Imatinib) 
that targets the mutant fusion protein Bcr-Abl and is used for the treatment of leukaemia. 
Another example is Vemurafenib that can inhibit the kinase of the mutation B-RAFV600E 
and is used to treat metastatic melanoma (5). The greatest advantage of targeted therapy 
is that allows to develop a personalized treatment for each patient according to the 
“characteristics” of their tumour. These (and others) are extensively reviewed in 
Shtivelman et al. (6) .  
1.2- Melanoma 
Melanoma is a type of skin cancer with its origin in mutated melanocytes. Although 
a minority amongst the other types of skin cancer (constituting less than 5% of all skin 
cancer cases), melanoma is responsible for over 80% of all skin cancer deaths (4).     
In the last decade, the incidence rate of melanoma has dramatically increased with an 
average increase of 3-8% per year that continues to rise annually (7). In the United States 
alone, there will be an estimated 73870 new cases and 9940 deaths for just 2015 alone 
(2). Men are more prone to develop malignant melanoma (1 in 34) than women (1 in 53). 
This is thought to be due to 
sex-specific behaviour and 
environmental exposure 
differences (2). 
Melanoma is a 
malignant neoplasm of 
melanocytes, cells specialized 
in producing melanin (skin 
pigment) that are localized 
within the basal layer of the 
epidermis (8). The 
transformation of 
melanocytes can arise from 
multiple sources such as 
accumulation of genetic alterations, interaction between environmental factors and 
impaired DNA repair. Melanoma spreads along the epidermis initially and as the tumour 
develops it invades in depth through the skin layers (Figure 1.2).    
Figure 1.2.1 – Progression of skin cancer. Squematic of 
histologic progress of melanoma throughout its many stages 
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The primary method to recognize a suspicious cutaneous lesion as early melanoma 
is the ABCDE acronym (asymmetry, border irregularity, colour variegation, diameter and 
evolving lesions) (8). This method is useful in early detection but it is limited since it 
cannot evaluate melanomas with vertical growth. This approach is complemented by 
dermoscopy, a non-invasive procedure that aids in the visualization of sub-surface 
structures (8).     
The staging of melanoma involves many parameters. Initially melanoma is 
classified based on the thickness (T), the number of lymph nodes affected (N) and the 
number of metastases (M) (9). Disease stage also takes in consideration ulceration, the 
rate of mitosis (expressed in number of mitosis per square millimetre of primary tumour) 
(8) and the levels of lactate dehydrogenase (LDH). The TNM categories are then 
combined to perform a stage grouping. These are summarized in Table 1.2.1, 1.2.2, 1.2.3 
and 1.2.4. 
 
 
Classification T Thickness (mm) Ulceration Status/Mitoses 
Tis (in situ) NA (not applicable) NA 
T1 ≤1,00 
a : whiteout ulceration and mitoses < 1/mm2 
b : with ulceration or mitoses ≥ 1/mm2 
T2 1,01 – 2,00 
a : whiteout ulceration 
b : with ulceration 
T3 2,01 – 4,00 
a : whiteout ulceration 
b : with ulceration 
T4 >4,00 
a : whiteout ulceration 
b : with ulceration 
Classification 
M 
Site 
Serum LDH (lactate 
dehydrogenase) 
M0 No distant metastases NA 
 M1a 
Distant skin, subcutaneous 
or nodal metastases 
Normal 
M1b Lung metastases Normal 
M1c 
All other visceral 
metastases 
Normal 
 Any distant metastases Elevated 
Table 1.2.1– Tumour thickness classification. According to the 7th edition of the Melanoma staging 
system by the American Joint Commission on Cancer (AJCC). 
Table 1.2.2 – Lymph nodes classification. According to the 7th edition of the Melanoma staging 
system by the American Joint Commission on Cancer (AJCC). 
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Stage Characteristics 
Classification 5 year survival 
rate T N M 
0 
Carcinoma in situ (in epidermis 
and has not spread to dermis) 
Tis N0 M0 99 – 100 % 
I A/B 
Lesions up to 2 mm but no 
nodal or distant metastases 
T1a N0 M0 
A – 95% 
B –88 - 92 % 
T1b N0 M0 
T2a N0 M0 
II A/B/C 
Lesions greater than 2 mm, no 
positive nodes or distant 
metastases 
T2b N0 M0 
A – 77 - 79 % 
B – 61 - 70% 
C – 43 - 45% 
T3a N0 M0 
T3b N0 M0 
T4a N0 M0 
T4b N0 M0 
III A/B/C 
Lesions of any size with positive 
lymph nodes 
Tx N1 M0 A – 57 – 73 % 
B – 41 – 57 % 
C – 20 – 34 % 
Tx N2 M0 
Tx N3 M0 
IV 
Lesions of any size with distant 
metastases 
Tx Nx M1 5 – 22 % 
Of all diagnosed melanomas, 90 % are superficial spreading melanoma, nodular 
melanoma and lentigno malignant melanoma (that are common in the elderly) (10). The 
Classification 
N 
No. of Metastatic Nodes Nodal Metastatic Burden 
N0 0 NA 
N1 1 
a : Micrometastasis 
b : Macrometastasis 
N2 2 – 3 
a : Micrometastasis 
b : Macrometastasis 
c : In transit metastases/satellites 
without metastatic nodes 
N3 
4 + metastatic nodes, or matted 
nodes, or in transit 
metastases/satellites with 
metastatic nodes 
 
Table 1.2.3 - Metastases classification. According to the 7th edition of the Melanoma staging 
system by the American Joint Commission on Cancer (AJCC).   
Table1.2.4 – Melanoma staging. According to the 7th edition of the Melanoma staging system by 
the American Joint Commission on Cancer (AJCC) and respective five-year survival rates. 
6 
 
remaining are acral lentiginous melanoma (palms of the hands and soles of the feet) or 
non-cutaneous melanomas (ocular, mucosal) (10). 
The standard treatment for advance melanoma has for many years been 
Dacarbazine (DTIC) that was approved by the Food and Drug Administration (FDA) in 
1975. Until 2011, DTIC used in combination with interleukin-2 (IL-2) was the only 
approved treatment for metastatic melanoma (4). Importantly, DTIC only has an average 
12% response rate (RR). In Europe, some countries use fotemustine as a 1st line therapy 
because this nitrosoureas drug has shown a RR of 12-27% (4).  
In 2011, Ipilimumab, a safer therapeutic has been approved. Ipilimumab is a 
recombinant monoclonal antibody raised against the cytotoxic T-lymphocyte associated 
antigen 4 (CTLA-4) that can help the immune response to tumour antigens (11). CTLA-
4 acts as an “immune checkpoint” that downregulates T-cell activation and prevents auto-
immunity (3). By blocking CTLA-4, Ipilimumab allows the re-establishment of the 
proper interaction between T-cell and the antigen presenting cell (10). Many clinical trials 
with Ipilimumab showed an increase in overall survival (OS) of patients independent of 
age, sex, stage of tumour or previous treatment(s) (4).  
Another group of successful chemotherapeutics is signal transduction small 
molecule inhibitors such as Vemurafenib, Dabrafenib and Trametinib. The first two are 
inhibitors of oncogenic BRAF-V600 protein kinase approved by the FDA in 2011 and 
2013, respectively (10). Since 40 – 50% of melanomas harbour a BRAF mutation, these 
drugs can oppose its oncogenic activities. Trametinib acts in similar way but it inhibits 
MEK, a substrate of BRAF (10). Despite good initial responses to these treatments, many 
tumours develop resistance to these inhibitors (4). Consequently, the investigation to 
increase the treatment “arsenal” and its many combinations remains imperative.   
        
1.3- The PI3K/AKT pathway 
Overall, DTIC has a very poor response rate in the majority of melanoma patients. 
As such, researchers are trying to identify common conserved mutations in deregulated 
signalling pathways in cancer that could be therapeutically targeted. One such pathway 
that has demonstrated a very high number of potential “drugable” molecules is the 
PI3K/AKT pathway. 
The PI3K/AKT pathway is a highly complex, critical cellular network involved in 
cell proliferation and survival (schematically represented in Figure 1.3.1) (12). This 
pathway is one of the most frequently mutated pathways (for example, the loss of PTEN) 
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in many human cancers where there is the constitutive activation of phosphatidylinositol-
3 kinase (PI3K). In non-transformed cells, following growth or other proliferative signals, 
PI3K phosphorylates inositol phospholipids generating phosphatidylinositol 3, 4, 5-
trisphosphate, (PIP3). PI3K is a heterodimer that is composed of a catalytic subunit (p110) 
and a regulatory subunit (p85) (13). Typically PI3K  is activated by either a receptor 
protein tyrosine kinase (RPTK) or a G-protein coupled receptor (GPCR) (13). The 
conversion of the plasma membrane lipid PI(4,5)P2 (PIP2) into PIP3 by active PI3K is 
extremely rapid (normally within seconds) (12). Once generated, PIP3 specifically binds 
to at least two distinct protein-lipid binding domains, principally the FYVE (Fab-1, 
YGLO23, Vps27 and EEA1) domain and/or pleckstrin homology (PH) domains (14). 
These PH domains are present in many proteins including the protein kinase B (PKB, also 
known as AKT) and the serine/threonine kinase 3’-phosphoinositide-dependent kinase 1 
(PDK1) (12). 
 
Figure 1.1.1 – Schematic of the PI3K/AKT pathway. Activation of RTK leads to recruitment of PI3K to 
the membrane and activation of the catalytic subunit. This initiates production of PIP3, which in turn 
recruits PDK1/2 and AKT. Activated AKT uses phosphorylation to activate and inhibit many different 
targets involved in cell survival, growth and proliferation. PTEN is a negative regulator of the pathway by 
converting PIP3 back to PIP2. 
AKT is a 57 kilo-Dalton serine/threonine kinase that acts by the phosphorylation of 
downstream protein targets. Mammalian species possess 3 AKT genes: AKT1, AKT2 and 
AKT3 (15). However their protein expression varies in a tissue-specific manner. AKT1 
expression is very high in brain, heart and lung. In contrast, AKT2 protein expression is 
highest  in skeletal muscle and embryonic brown fat tissue (16). AKT3 is predominantly 
expressed in brain, kidney and embryonic heart(17).  
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Following AKT/PIP3 binding, AKT is activated by PDK1 and is phosphorylated at 
the threonine 308 residue (Thr308) (18). A secondary phosphorylation occurs at serine 
473 (Ser473) by the action of different kinases such as mammalian target of rapamycin 
complex 2 (mTORC2) and integrin-linked kinase (ILK) (19). Although a dual 
phosphorylation is necessary for a full activation of AKT, a Thr308 p-AKT is still capable 
of phosphorylate some but not all of its substrates. 
The active AKT is translocated (by a currently unknown mechanism) from the cell 
membrane into the cytoplasm and from here, into many others cellular compartments 
(including the nucleus, Golgi, endoplasmic reticulum and mitochondria), where its target 
substrates are located (19,20). Once activated, AKT inhibits the GSK3 (glycogen 
synthase kinase 3) protein by direct phosphorylation (20). With GSK3 inhibition, its 
targets such as β-catenin are not phosphorylated, which impedes their degradation. This 
allows β-catenin to translocate to the nucleus, where it interacts (both directly and 
indirectly) with transcription factors to regulate the expression of several genes such as 
cyclin D1. Cyclins are proteins which are involved in cell cycle checkpoints, in 
combination with cyclin-dependent kinases (CDKs) to regulate the cell cycle (21). The 
cyclin D1 protein is very important because not only is it a positive regulator for the G1/S 
checkpoint transition in the cell cycle, but it is also a direct target of GSK3β (22). Cyclin 
D1 binds to CDK4, forming a cyclin/CDK complex that phosphorylates the 
retinoblastoma protein (Rb). The phosphorylation of Rb leads to the activation of genes 
required for the cell cycle progression (23). As such, AKT can positively regulate G1/S 
cell cycle progression through inactivation of GSK3β and nuclear accumulation of cyclin 
D1.    
AKT can also stop the inhibition of Cyclin/CDK complexes by the phosphorylation 
of p21Waf1/Cip1 (p21) and p27Kip2 (p27) (24,25). Once phosphorylated, the p21 protein is 
retained in the cytoplasm and cannot inhibit the cyclin D-CDK4 complex while p27 is 
relocated from the nucleus into the cytoplasm, preventing p27-mediated  inhibition of 
cyclin E-Cdk2 and cyclin A-Cdk2 (19). 
AKT can also affect protein synthesis through regulation of mTOR (mammalian 
target of rapamycin). The mTOR protein is a serine/threonine kinase that exists in two 
different protein complexes: mTORC1 and mTORC2 (26). Among its components, a 
relevant difference between them is the Raptor (regulatory-associated protein of mTOR) 
accessory protein in complex 1 and Rictor (rapamycin-insensitive companion of mTOR) 
accessory protein in complex 2 (26). mTORC1 can elevate mRNA translation by 
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activating the p70 ribosomal protein S6 kinase (p70S6K1) and inhibiting the repressor 
eIF4E-binding protein (4E-BP) (27). The regulation of mTORC1 is by the tuberous 
sclerosis complex (TSC), a heterodimer of hamartin (TSC1) and tuberin (TSC2). The 
TSC acts as a GTPase-activating protein (GAP) that negatively regulates Rheb (RAS 
homolog enriched in brain), a small GTPase that is required for mTORC1 activation (27). 
AKT can phosphorylate TSC2, impeding the formation of the TSC complex and leading 
to the activation of mTORC1.  
Another interesting interaction between AKT and mTOR is through the mTORC2. 
This complex can regulate metabolism, cytoskeleton (28) and it can also phosphorylate 
AKT at Ser473 (26,27). Additionally, mTORC2 can phosphorylate the Thr450 residue 
upon the translation of nascent AKT, implying that mTORC2 activity is regulated by 
signals that promote AKT translation (28).  
AKT can also promote cell survival by activating the cyclic AMP-response element 
binding protein (CREB). Phosphorylation of CREB induces the binding of accessory 
proteins that are needed for the transcription of anti-apoptotic genes, including Bcl-2 (B-
cell lymphoma 2) and Mcl-1 (myeloid cell leukaemia 1) (19). Related to this function, 
AKT can affect apoptosis by the phosphorylation of BAD (Bcl-2-associated death 
promoter). Bad controls the release of cytochrome c from mitochondria to initiate the 
caspase cascade, a process that is critical for the induction of apoptosis (12). BAD can 
also bind to Bcl-2 or Bcl-XL (B-cell lymphoma-extra-large), therefore blocking their anti-
apoptotic activities (19). When phosphorylated by AKT, the BAD-Bcl-2/Bcl-XL 
complexes are disrupted and BAD is bound instead to the 14-3-3 chaperon protein, being 
sequestered into the cytosol. In addition, AKT will also phosphorylate BAX (Bcl-2-
associated X protein), blocking its translocation to the mitochondria (19). Another way 
that AKT directly affects the apoptotic response is the inactivation of pro-caspase9, 
impeding the initiation of caspase cascade, and the phosphorylation of MDM2 (murine 
double minute 2), leading to the inhibition of p53-mediated apoptosis (19). A critical AKT 
protein target are the members of the FOXO (Forkhead box O) family of transcription 
factors including FOXO1a, FOXO3a and FOXO4 (19). These transcription factors have 
an essential role in promoting apoptosis and inducing cell cycle arrest. These (FOXOs 
and p53) are discussed in depth in section 1.4 and 1.5 respectively.  
AKT can also activate the inhibitor of kappa B kinase-α (IKKα), leading to the 
phosphorylation of I-kappa-B (I-kB), marking it for degradation and stopping its 
inhibitory function over NF-kB (nuclear factor kappa-light-chain-enhancer of activated 
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B cells) (19). The free NF-kB can translocate to the nucleus and stimulate the transcription 
of pro-survival genes including the inhibitor of apoptosis protein 1 (IAP1)  and IAP2 (19). 
The PI3K/AKT pathway is negatively regulated by PI-3, 4, 5-P3 phosphatases 
including the phosphatase and tensin homologue deleted on chromosome 10 (PTEN) 
(12,29). This phosphatase dephosphorylate PIP3 into PIP2, thus preventing the activation 
of AKT. Other phosphatases capable of regulating this pathway are protein phosphatase 
2A (PP2A) and the pleckstrin homology domain leucine-rich repeat protein phosphatase 
(PHLPP) family (19). These phosphatases are able of dephosphorylating the thr308 and 
ser473 AKT residues respectively, thus inactivating the network.  
 
1.4- FOXO proteins 
The Forkhead box O (FOXO) family are transcription factors with a highly 
conserved DNA binding domain (30). In mammalian cells, four FOXOs have been 
identified: FOXO1, FOXO3a, FOXO4 and FOXO6. FOXOs can act either as 
transcriptional activators or as repressors, depending on additional co-factors recruited 
alongside them when they are bound to DNA (30). FOXOs are critical effectors of the 
PI3K pathway and when growth factors, cytokines or hormones activate the PI3K 
pathway, FOXOs are phosphorylated by AKT and are bound by the 14-3-3 chaperon 
protein (31,32). This FOXO/14-3-3 complex formation prevents FOXO-DNA binding 
and directs the cytoplasmic retention of FOXOs (30). Other kinases have been identified 
that are able to induce the cytoplasmic relocation of FOXO, such as serum- and 
glucocorticoid-inducible kinase (SGK), cyclin-dependent kinase- 2 (CDK2) and IκB 
kinase (33). By directing the cytoplasmic accumulation of FOXOs (and their subsequent 
ubiquitin-dependent proteomic degradation), activated AKT can prevent FOXO-
dependent gene transcription preventing cell cycle arrest and apoptosis (summarized in 
figure 1.4.1).  
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FOXOs have a major role in proliferation, apoptosis, metabolism, inflammation, 
differentiation and stress resistance (32). Amongst the genes currently known that are 
regulated by FOXOs are p27, p21, p15 and p19. The p15 and p19 proteins are Cdk 
inhibitors that block the binding of cyclin D to CDK4 and CDK6 (30).  As mentioned 
before, the p27 and p21 proteins are also CDK inhibitors necessary for cell cycle 
checkpoints regulation. Through the regulation of the expression of these genes/proteins, 
FOXOs are able to modulate the G1/S and G2/M transition of the cell cycle. In addition, 
it has been showed that activation of FOXO3 alone is sufficient for p27 upregulation and 
inhibition of proliferation (30).  
During oxidative stress, FOXOs can coordinate the regulation of manganese 
superoxide dismutase (MnSOD) and catalase expression to decrease oxidative damage 
and increase cellular survival (30,34). Another way that FOXOs favours cell survival is 
by maintaining energy homeostasis through Sestrin3 (Sesn3) and Rictor expression. 
Inducing the expression of these genes results in inhibition of mTORC1 activity (major 
energy consumer) and an increase of mTORC2 activity, leading to the activation of AKT 
(which increase energy metabolism) (27).      
In regard to regulating apoptosis, FOXOs can modulate the expression of BIM (Bcl-
2 interacting mediator of cell death, also known as BCL2L11), PUMA (p53 upregulated 
modulator of apoptosis) and Bcl-6 to induce the intrinsic apoptotic pathway. 
Alternatively, FOXOs upregulate the death receptor ligands FasL (Fas-ligand, also 
Figure 1.4.1 - Schematic of FOXO cytoplasmic translocation and sequential degradation. 
Activated AKT translocate to the nucleus (unknown mechanism) and phosphorylates FOXO. FOXO is then 
translocated to the cytoplasm where it suffers polyubiquitination and subsequent degradation.  
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known as CD95L) and TRAIL (tumour necrosis factor-related apoptosis inducing ligand) 
to activate the extrinsic apoptotic pathway (30). FasL is the key death factor of receptor-
triggered programmed cell death in immune cells (35,36). It has an important role in 
termination of immune responses, elimination of autoreactive cells and the establishment 
of immune privilege. Tumour cells that constitutively express FasL on their surface are 
able to generate a tumour-associated immune privilege, evading the immune surveillance 
and even kill tumour infiltrating lymphocytes (35). It has also been shown that FOXOs 
also play a role in preserving the self-renewal capacity of hematopoietic stem cells (33).    
FOXO factors have been shown to be deregulated in many types of cancer such as 
breast, prostate, glioblastoma, rhabdomyosarcoma and leukaemia (33). Because of their 
role in regulating genes involved in apoptosis and cell cycle arrest, inactivation of FOXOs 
is an important step in tumorigenesis. As tumour suppressor genes, FOXOs are of extreme 
importance in the development of treatments against cancer. The study of how the many 
different signalling pathways affect the FOXO proteins have already shown that these 
factors are need for the current chemotherapeutics to have a cytostatic or cytotoxic effect 
on tumour cells (31,33). As such, FOXOs can be considered as biomarkers for treatment 
prognostics and risk assessment of patients. For example, cytoplasmic location of 
FOXO3a correlates with poor survival in breast cancer (33).  New drugs that can influence 
the expression of FOXOs or that can affect their subcellular translocation will bring 
alternative approaches to chemotherapy. Combination treatments with drugs that activate 
FOXO can synergize with standard chemotherapeutics to sensitize tumour cells, opening 
new ways to counteract cancer resistance. However, the use of FOXO transcription 
factors must be well study because their ability to activate survival signalling and 
feedback mechanisms between FOXO family members may limit clinical utility.  
The role of FOXOs on melanoma ranges from initial tumorigenesis all the way to 
treatment resistance. Melanoma is known to have the PI3K pathway constitutively active 
from either mutation of RTKs, PI3K or loss of PTEN. With AKT constantly active, the 
phosphorylation of FOXOs and its subsequent degradation will lead to uncontrolled 
proliferation. As for resistance, given that many current chemotherapeutics need FOXOs 
to exert their cytostatic/cytotoxic effect, tumour cells can counter treatments with cross-
talk between signalling pathways that have FOXO as a common downstream target. For 
example, FOXO3a is a common target of three oncokinases: AKT, IKK and ERK (33). 
All three kinase-mediated phosphorylation induce FOXO3a ubiquitination and 
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subsequent degradation. Reverting their action over FOXO3a can re-sensitize tumour 
cells to chemotherapeutics.      
1.5- The tumour suppressor p53 
Similar to FOXO-family members, the tumour suppressor protein p53 is a 
transcription factor that regulates many genes involved in cell cycle arrest, apoptosis, 
senescence, autophagy and metabolism. Due to the importance of p53 in multiple cellular 
networks and preserving the cells genome, p53 is commonly referred to as “the guardian 
of the genome”(37). 
Under normal cellular conditions, p53 exists in the cell bound to its negative 
regulator MDM2 (murine double minute 2) (schematically represented in Figure 1.5.1). 
In response to stress signals (for example DNA damage), p53 can be phosphorylated, 
abrogating the MDM2 interaction, allowing p53 levels to accumulate leading to the 
transcriptional induction of a vast array of target genes (37,38).   
 
When MDM2 is phosphorylated, it will shift the balance p53/MDM2 in three ways 
(37). First, it abrogates the transcriptional activity by binding to the N-terminal of the 
transactivation domain of p53. Second, it induces nuclear export of p53 through mono-
ubiquitination. Lastly, it destabilizes p53 through poly-ubiquitination and subsequent 
proteasomal degradation (Figure 1.5.1). 
Figure 1.5.1 - Schematic of p53 degradation. 
Activated AKT phosphorylates Mdm2, which in turn will bind to p53. P53 then suffers ubiquitination and 
is degraded by proteasomes. 
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As an E3 ubiquitin ligase, MDM2 has the ability to attach an ubiquitin chain of 76 
amino acids to its target protein (38). This action is facilitated by MDM4, an E4 ligase 
(also known as ubiquitin chain elongating factors) that mediates the elongation of the 
ubiquitin chain previously established by MDM2 (38). Importantly, Mdm2 is a 
transcriptional target of p53, creating a feedback loop between them. This loop is the 
primary mode through which p53 autoregulates its levels. 
The p53 transcription factor has always been of major interest in the fight against 
cancer. Because of its diverse biological functions that thwart tumorigenesis, the status 
of p53 has become a standard evaluation in cancer patients. In fact, p53 is the most 
mutated gene in human cancer, with a mutation rate that varies from 5% to 95% according 
to tumour type (39). Most mutations occur in the DNA binding domain. Even if the 
tumour cells retain the wildtype p53, it is often non-functional through its regulation 
mechanisms being altered (40). 
In chemotherapy, p53 has an important role in chemosensitization and 
radiosensitization of tumour cells. As such, drug development is focusing p53 in four 
different approaches 1) activate wildtype p53, 2) reactivate mutant p53, 3) selectively kill 
cells with mutant p53 and 4) temporally inhibit wildtype p53 for normal cell protection 
(40).          
In the particular case of melanoma, p53 has a mutation frequency of 10-20%. This 
is curious given that the background mutational load of melanoma is one of the highest 
in human cancer, comparable to lung and colon cancer (39). Although melanoma retains 
a wildtype p53, its functions are inactivated by other means. One way is through the 
deletion of CDKN2A (cyclin-dependent kinase inhibitor 2A), which leads to the loss of 
p14ARF, an inhibitor of MDM2 that prevents the targeting of p53 for degradation. Another 
mechanism is through the amplification of MDM2, leading to the destabilization of 
p53/MDM2 homeostasis (39,41). 
Another possibility is the constitutive activation of the PI3K pathway. AKT 
phosphorylates MDM2 in both the nucleus and the cytoplasm, leading to the degradation 
of p53 through the methods described above. This link between p53 and AKT is of 
extreme importance in the development of new treatments for melanoma. 
1.6- Novel Therapeutics in the Treatment of Melanoma 
With modern drug development, many new drugs are being developed focusing in 
the cross-talk between different signalling pathways as a way to avoid resistance. As seen 
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with Vemurafenib, cancer cells can “counter-act” the inhibition of BRAF by, for example, 
re-activation of downstream targets such as ERK (4). A way to delay or circumvent the 
resistance to BRAF inhibitors is to combine them with MEK inhibitors such as 
Trametinib, which is being tested in clinical trials.  
A key example of combined targeted therapies is the PI3K/AKT pathway. As this 
pathway interacts with and signals via RAS/RAF/MEK/ERK components at multiple 
points, resulting in cross-activation, cross-inhibition and pathway convergence, these 
targets could, in principle be individually targeted in combinational therapy to either 
restore drug sensitivity or to reduce the possibility of emerging resistant cancer cells(3).  
This is particularly noted in breast cancer resistance. Trastuzumab (marketed as 
Herceptin) is a recombinant monoclonal antibody that binds to the extracellular domain 
of HER2 (Human Epidermal growth factor Receptor 2) (42) and used to treat HER2+ 
breast cancers. Trastuzumab blocks the formation of HER2-HER3 heterodimers and also 
the binding of HER3 to PI3K (43). Many laboratory models of resistance have 
demonstrated that the loss of PTEN can reduce the anti-tumour effect of Trastuzumab as 
well as mutational activation of PI3K (42). As a consequence of this, many PI3K and 
AKT inhibitors are being tested in clinical trials as a means to reverse resistance to 
Trastuzumab in dual treatment regimens(43,44). 
The PI3K, mTOR and AKT inhibitors can be used in many types of cancer, since 
they can target one of the most mutated pathways in human cancer. The mTOR inhibitors 
such as rapamycin and everolimus to test the PI3K signalling blockade in melanoma 
through inhibition of mTORC1 (45). Unfortunately, the efficacy of mTORC1 inhibitors 
is limited by dysregulation of negative feedback loops (45). PI3K inhibitors, such as 
wortmannin and LY294002 (46), and AKT inhibitors, such as afuresertib and MK2206 
(44,47), showed positive results in pre-clinical models (47). Although positive, this 
results only confirmed that single-agent inhibition of the PI3K/AKT pathway is often 
cytostatic rather than cytotoxic, with activation of compensatory pathways (48).  
The development of dual PI3K-mTOR inhibitors, such as NVP-BAG956, NVP-
BBD130 and NVP-BEZ235, was an important step that showed impressive 
antiproliferative activity both in vitro and in vivo (45,46). In particular, BEZ235 is a 
potent pan-PI3K inhibitor that blocks mTOR by targeting the ATP-binding site of 
mTORC1/mTORC2 (46)  and is currently in clinical trials (47,49). As mentioned before, 
cross-talking between signalling pathways has become a focus in the development of new 
therapies. The dual PI3K/mTOR inhibitors can synergize with BRAF and MEK 
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inhibitors, sensitizing back tumours who previously acquired resistance to this drugs (50–
52). A prime example is the combination of Vemurafenib with BEZ235, currently being 
tested in pre-clinical studies but already showing promising results. More combinatorial 
targeted therapies are extensively reviewed in Grazia et al. (47).        
Another approach is the improvement of immunotherapies and their combination 
with cytotoxic agents and/or targeted therapies. Nivolumab (BMS-936558, MDX – 1106) 
is a fully human IgG4 antibody that blocks the PD-1 (programmed death 1) receptor. PD-
1 interacts with PD-L1 ( Programmed death ligand 1), inhibiting T-cell proliferation and 
cytotoxic functions (4). The interaction PD-1/PD-L1 plays an important role in tumour-
induced immunosuppression in many advanced malignancies. Nivolumab has 
demonstrated clinical activity in patients with melanoma, renal-cell carcinoma and non-
small-cell lung cancer (NSCLC) (10). Currently, a combination of Ipilimumab and 
Nivolumab is being studied and already shows early phase results of rapid and deep 
response of 80% (NCT01783938; NCT01024231) (53). 
An alternative to complement current therapies is the use of phytochemicals. These 
are naturally occurring chemical compounds such as flavonoids and phytoalexins that can 
be found in common food (peanuts, red wine, grapes, strawberries, etc.).Phytochemicals 
are remarkably nontoxic and have proven their ability in preventing the development of 
cutaneous malignancies (45). They are currently being studied as potential adjuvant 
therapies for metastatic melanoma (45).  
1.7- The Tribble2 homolog 
Originally identified as tribbles in Drosophila, TRIB2 is pseudokinase which 
functions as a signalling modulator and mediator (54). Mammalian cells possess three 
Trib homologs: Trib1, Trib2 and Trib3 (55). All three Trib have been associated with 
human malignancies by interacting with pathways involved in cell survival and apoptosis. 
Trib proteins interact with many signalling molecules and transcription factors such as 
activating transcription factor 4 (ATF4), p65, mitogen-activated protein kinase kinase 
(MAPKK), AKT and constitutive morphogenesis 1 (COP1) (55).  
Like all Trib proteins, TRIB2 has three main domains: an N-terminal, a C-terminal 
and a kinase domain. It belongs to the pseudokinase family because its central region 
(kinase domain) possess high homology with serine/threonine kinases but deviations in 
the catalytic loop eliminates its catalytic activity (Figure 1.7.1). Although it is a 
phosphoprotein, it is theorized that TRIB2 is unable of autophosphorylate itself (55). 
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TRIB2 has two important motifs on its C-terminal domain: MEK1 and COP1 
binding sites. Through the MEK1 motif, TRIB2 is able to interact with the 
RAS/MEK/ERK signalling pathway and enhance ERK phosphorylation (54). TRIB2 can 
bind to COP1, an E3 ubiquitin ligase, through the COP1-binding site and promote 
proteasome-mediated degradation (54). One known target is the C/EBP 
(CCAAT/enhancer-binding protein) family of transcription factors. By facilitating 
C/EBP-α degradation, TRIB2 aids in myeloid differentiation. This characteristic marked 
TRIB2 as an oncogene for acute myeloid leukaemia (AML). (54,56). Further studies 
brought to light that TRIB2 is commonly overexpress in many types of cancer such as 
lung adenocarcinoma, cervical carcinoma, liver cancer and malignant melanoma (55–59). 
In the case of melanoma, TRIB2 can be used as a biomarker since its expression correlates 
with the tumoral progression (60). 
Another important fact is that TRIB2 was found to be a negative regulator of the 
FOXO family of transcription factors (59). TRIB2 can interact with AKT, leading to the 
inactivation and degradation of FOXO proteins. This implies that TRIB2 may be involved 
in mechanisms of cancer resistance. 
Since TRIB2 is a pseudokinase, the mechanisms through which it exercises its 
functions is currently unknown. The main possibility is that TRIB2 acts as an adaptor that 
binds multiple proteins and brings them together. Given its proven role over FOXOs and 
in tumorigenesis, elucidation of how TRIB2 interacts and activates survival signalling 
can be an important step in cancer treatment. 
1.8- Hypothesis 
The previous work of our group showed that TRIB2 is a biomarker of diagnosis and 
progression of melanoma. Recent studies in our laboratory revealed that TRIB2 involved 
in mechanisms of drug resistance to many chemotherapeutics, including PI3K inhibitors 
currently in clinical trials. Based in our research, this work intends to characterize the 
TRIB2 pseudokinase following PI3K inhibition, its regulation, the domain responsible 
Figure 1.7.1 - Representation of TRIB2. Kinase domain and C-terminal are highly conserved, with two 
binding motifs for MEK1 and COP-1. 
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for the activation of survival signalling molecules such as AKT and how it relates to drug 
resistance in cancer. 
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2. Materials and Methods 
2.1- Cell lines and reagents 
The human cell lines HEK293T (embryonic kidney cells), U2OS [p53+/+], were 
maintained in DMEM supplemented with 10% FBS (Sigma, PT) and antibiotics (Gibco, 
US). Antibodies used in my studies are shown in Table 2.1.1 and were used for our 
immunoblots. Signal visualization was achieved using a ChemidocXRS+ system 
(BioRad, PT). Dacarbazine (Sigma, PT), gemcitabine hydrochloride (Eli Lilly #VL7502), 
AKT inhibitor VIII (Calbiochem, US), BEZ235 (Novartis, US), BAY806946, BAY 
1082439, BAY1001931 (a gift from Bayer Healthcare, Germany), rapamycin (Sigma, 
PT), actinomycin D (Sigma, PT), and cycloheximide (Sigma, PT) and MG132 (Sigma, 
PT) were used at the following concentrations (Actinomycin D (ActD) 5 μg/ml, 
Cycloheximide (CHX) 50 μg/ml, MG132 at 1 μM).  
Primary Antibodies Species Information Supplier 
Actin goat I-19; sc-1616 Santa Cruz Biotechnology 
Total AKT goat C-20; sc-1618 Santa Cruz Biotechnology 
p-AKT rabbit Ser473; sc-7985 Santa Cruz Biotechnology 
BIM rabbit H-191; sc-11425 Santa Cruz Biotechnology 
P27 mouse F-8; sc-1641 Santa Cruz Biotechnology 
MDM2 rabbit C-18; sc-812 Santa Cruz Biotechnology 
p-MDM2 rabbit Ser 166; sc-293105 Santa Cruz Biotechnology 
p-Mdm2 rabbit S166; 3521S 
Cell Signalling 
Technology 
Lamin A/C mouse N-18; sc-6215 Santa Cruz Biotechnology 
TRIB2 rabbit custom 
Home-made, generated at 
CNIO (Madrid, Spain) 
FasL rabbit C-178; sc-6237 Santa Cruz Biotechnology 
Total Foxo3a 
(FKHRL1) 
goat N-16; sc-9813 Santa Cruz Biotechnology 
p-Foxo3a (p-
FKHRL1) 
rabbit Ser 253; sc-101683 Santa Cruz Biotechnology 
Table 2.1.1- Primary antibodies used. Datasheets of each antibody are on Appendix A1-A11.  
2.2- Western blot analysis  
For the preparation of whole cell lysate, cells were harvested and lysed using RIPA 
buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.5% Na-deoxychlorate, 150 mM NaCl, 1 
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mM EDTA, 2 mM NaF, 2 mM NaVO4 and 1x protease inhibitor cocktail (PIC) (Sigma). 
We used the Bradford assay, with the Quick Start TM Bradford 1x Dye Reagent (Bio-
Rad). We prepare PCR tubes with 99 μl of Bradford. We dilute 1 μl of sample in 10 μl of 
H2O. We then add 1 μl of the dilution to the tubes. The blank tube was prepared with 100 
μl of Bradford only. We analysed in the Nanodrop 2000/2000c Thermo Scientific by 
using 2 μl of each tube. For SDS–PAGE, protein samples were boiled for 5–10 min in 
protein sample buffer (50 mM Tris pH 6.8, 1% SDS, 10% glycerol, 0.01% Bromophenol 
Blue, β-mercaptoethanol [50 µL per 950 µL sample buffer]). Following electrophoresis, 
proteins were transferred onto nitrocellulose membrane (BioRad). The membrane was 
blocked for 1 hour at room temperature or overnight at 4°C 5% BSA 0.1% tween20 
blocking buffer. Primary antibodies were added to the membrane (Supplemental Table 1) 
overnight at 4°C or for 2 hours at room temperature. Secondary antibody was added 
(Supplemental Table 2) at typically 1:5000 dilution for 1 hour at room temperature. 
Visualization of signal was achieved using a ChemidocXRS+ Imaging System (BioRad). 
Secondary 
Antibodies 
Species Information Supplier 
Anti-rabbit goat IgG-HRP; sc-2030 Santa Cruz Biotechnology 
Anti-goat donkey IgG-HRP; sc-2020 Santa Cruz Biotechnology 
Anti-mouse goat IgG-HRP; sc-2005 Santa Cruz Biotechnology 
Anti-mouse rabbit IgG; A9044 Sigma 
Table 2.2.1 – Secondary antibodies used. Datasheets of each antibody are on Appendix A12-A15. 
2.3- Constructs 
A 3062 bp fragment encoding the entire human Trib2 (hTRIB2) cDNA was sub-
cloned into pEGFP-N1 or pIREPuro2 plasmids, (one co-expressing GFP, the other 
containing a V5 tag.). Full length human TRIB2 (hTRIB2, 1-343 aa), dN (63-343aa 
hTRIB2, dC (1-304 aa) hTRIB2, KD (63-304 aa) hTRIB2, NT (ΔCT, 1-250 aa) hTRIB2, 
CT (ΔNT, 270-343 aa) hTRIB2 and ΔCOP1 hTRIB2 were kindly provided by W.S. Pear 
and shown in Table 3. Each was cloned into pMigR1-myc plasmid (55). All cDNAs were 
sequenced in their entirety to verify there were no mutations in any of our constructs. 
Each construct was transfected (Polyplus Transfection jetPRIME® transfection reagent) 
following the manufacturers guidelines (Appendix B). After transfection, the plates were 
incubated for 24 hours or selection and screening initiated. 
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Plasmids 
constructs 
Mutant 
#1 Full length TRIB2 
#2 Δ COP1 
#3 Δ N 
#4 Δ C 
#5 Kinase domain 
#6 C term 
#7 N term 
Table 2.3.1 – TRIB2 plasmids constructs used 
2.4- Flow cytometry cell cycle analysis 
Cells were grown to 70% confluence. Cells were mock treated/exposed to each 
compound for the time points indicated. Samples were collected, washed (PBS) and fixed 
(70% ethanol). Ethanol was removed and samples were ressuspended in PBS. Propidium 
iodide (2.5 mg mL) was added to each sample. Samples were run on a Fluorescence 
Activated Cell Scanner (FACS) and the percentage populations (sub-G1, G1, S and G2 
phases) determined. 10,000 total events were scored per study Data was analysed using 
Infinicyt (Cytognos). 
 
2.5- FACS sorting 
Cells were grown to 70% confluence. Cells were mock treated/exposed to each 
compound for the time points indicated. Samples were collected, washed (PBS) and fixed 
(70% ethanol). Ethanol was removed and samples were ressuspended in PBS. Samples 
were run on a Fluorescence Activated Cell Sorter (FACS) and the GFP positive and GFP 
negative populations separated. 50,000 total events were scored per study. Data was 
analysed using Infinicyt (Cytognos). The sorted samples were stored at 4⁰C until the 
following day prior to sample collection for immunoblotting.  
 
2.6- Immunoprecipitation 
The samples sorted by FACS were collected with 50 μl each of total protein lysis 
buffer (50 mM Tris pH 7.5, 1% NP-40, 0.1% Na-deoxychlorate, 130 mM NaCl, 5 mM 
EGTA, 10 mM NaF, 2,5 mM NaVO4 and 1x protease inhibitor cocktail (PIC)). Stored at 
-80⁰C for 24 hours. On the following day, added to each sample 5 μl of antibody and left 
them spinning on the “end-over-end” overnight at 4⁰C.  
Figure 2.3.1 – Schematic of TRIB2 mutants. Different 
regions deleted in the TRIB2 plasmids constructs. 
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Prepared beads with Protein G Sepharose Fast Flow (20 μl/sample) and PBS. Spin 
for 2 minutes at 1.300 rpm. Ressuspended with 1ml PBS and spin again. Repeated the 
last step but added PBS in an equal amount to the total volume of beads. Added 20 μl of 
the beads solution prepared and 300 μl of PBS to each sample. Left the samples spinning 
in the “end-over-end” for 1 hour at room temperature. Centrifuged for 2 minutes at 1.300 
rpm. Removed supernatant and kept the beads. Added 300 μl of PBS and repeated the 
spin. Removed the supernatant and prepared the samples with 30 μl of 2x laemmli buffer. 
Boiled the samples for 5 minutes at 98⁰C. Proceeded by following the western blot 
protocol indicated above by loading 25 μl of each sample to the gel.    
 
2.7- Co-Immunoprecipitation 
Cells were harvested using total protein lysis buffer (50 mM Tris pH 7.5, 1% NP-
40, 0.1% Na-deoxychlorate, 130 mM NaCl, 5 mM EGTA, 10 mM NaF, 2,5 mM NaVO4 
and 1x protease inhibitor cocktail (PIC)). We used the Bradford assay and the Nanodrop 
2000/2000c Thermo Scientific for protein quantification, as mentioned above. 
Prepared α-GFP probes with Protein G Sepharose Fast Flow, antibody against GFP 
and PBS. Spin the probes for 1 h in the “end-over-end” at room temperature. Centrifuged 
for 1 minute at 1.300 rpm. Washed 2 times with PBS. Ressuspended with PBS. 
Calculated amounts required for 250 μg of protein, probe and PBS for each sample. Add 
all to an Eppendorf and spin again in the “end-over-end” for 1h. Centrifuged for 1 minute 
at 1.300 rpm. Washed 2 times with 1 ml of PBS. Removed the supernatant and eluted 
with 50 μl of 2x Laemmli buffer. Boiled the samples for 5 minutes at 98⁰C and stored 
them at -80⁰C. 
 
2.8- RNA extraction/First strand cDNA protocol 
We used the TRI-reagent protocol from Sigma (Appendix C). The resulting RNA 
samples were then used to make first strand cDNA with NZY First-strand cDNA 
Synthesis Kit from Nzytech (Appendix E). Samples were stored at -18⁰C.  
 
2.9- qRT-PCR /DNA electrophoresis agarose gel (1 %)/Primer validation 
We used the LuminoCt® SYBR® Green qPCR Ready MixTM protocol from Sigma 
(Appendix F). 
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Primers Supplier 
GAPDH Nzytech 
TRIB2 Nzytech 
PTEN Nzytech 
MDM2 Nzytech 
FasL Nzytech 
P27 Nzytech 
TRAIL Nzytech 
Cyclin D1 Nzytech 
P19 Nzytech 
BIM Nzytech 
P21 Nzytech 
Table 2.9.1 – List of primers used 
We then ran a 1% agarose electrophoresis gel to analyse the amplified products. 
 
2.10- Chromatin Immunoprecipitation assay (ChIP) 
The plates were washed with ice-cold 1x PBS twice and added a 1% 
formaldehyde/PBS solution to each for cross-linking the proteins with the DNA. Plates 
were incubated at 37⁰C for 10 minutes and washed again with ice-cold 1x PBS twice. 
The plates were scraped with 1 ml Scrape buffer (1M Tris-HCL with 10 mM DTT), 
collected in eppendorfs and incubated in water bath at 30⁰C for 15 minutes. The tubes 
were centrifuged and washed with ice-cold 1x PBS, Buffer I (10% Triton X-100, 100 mM 
EDTA, 100 mM EGTA, 0,5 M HEPES) and Buffer II (100 mM EDTA, 100 mM EGTA, 
0,5 M HEPES in 5M NaCl) . The pellets were ressuspended with Lysis buffer (10 % SDS, 
EDTA, Tris pH 8.0) prepared with PIC (protease inhibitor complex). The samples were 
sonicated 5-6 times, 10 seconds each, to break the DNA into approximately 250 base 
pairs fragments. The samples were then centrifuged at 15.000 rpm, 4⁰C for 10 minutes. 
The supernatant was transferred to new eppendorfs and we added 300 μl of Buffer 
D (10% Triton X-100, 100 mM EDTA, Tris pH 8.0, NaCl) with PIC. We then removed 
100 μl to the input eppendorfs. These input samples were left in the heat block at 65⁰C 
overnight (to reverse the cross-link). To the remaining samples we added antibody (5μl 
per sample) and left overnight at 4⁰C. 
On the following day, we removed the input samples from the heat block and stored 
them at -20⁰C. Added protein G-fast flow beads (Sigma) to samples (10μl per sample) 
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and rotated for 1 hour at room temperature. Washed samples with TSE I (10% SDS, 1% 
Triton X-100, 100 mM EDTA, 3% NaCl (5M) in Tris pH 8.0), TSE II (10% SDS, 1% 
Triton X-100, 100 mM EDTA, 16% NaCl (5M) in Tris pH 8.0) and TSE III (1% NP-40, 
100 mM EDTA, 10% Tris pH 8.0, 1% deoxycholate in LiCl (1M)) with rotation and 
centrifugation between washes. Washed 3 times with ice-cold TE buffer. Added a 
solution of SDS and NaCHO3 to each sample and rotated for 1 hour at room temperature. 
Transferred the supernatant to new eppendorfs, left them overnight on the heat block at 
65⁰C and stored them at -20⁰C on the next day. 
We used the NzyGelpure purification kit (Appendix D) to “clean” the previous 
ChIP and input samples. We used 1 ml of binding buffer on step 1 and 30 μl of dH2O on 
step 5 instead of the manufacturer indications. The purified DNA was stored at -20⁰C. 
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3. Results 
3.1- TRIB2 protein levels increase in the presence of PI3K inhibitors 
Our group has previously demonstrated that TRIB2 is a biomarker for malignant 
melanoma (60) and is a negative regulator of FOXO3a (59).  As such, we know that 
TRIB2 is integrated within the PI3K pathway but where within this network and 
specifically how TRIB2 can 
regulate FOXO3a is 
unknown. We have 
previously generated a range 
of isogenic TRIB2 expressing 
cell lines and obtained a 
number of novel PI3K 
pathway inhibitors 
(summarized in Figure 3.1.1).  
We first questioned if there 
were any effects on the 
TRIB2 protein before and after PI3K inhibition within our isogenic cell lines. Using an 
immunoblotting approach, we found a discernible increase in TRIB2 protein in both the 
endogenous U2OS-Empty and the U2OS-TRIB2 cell lines (Figure 3.1.2).  
 
 
 
 
Figure 3.1.1- PI3K pathway inhibitors.  
Squematic of PI3K pathway and how the inhibitors target its 
components. 
Figure 3.1.2- TRIB2 protein levels increase 
following PI3K inhibition.  
Representative western blot of isogenic 
osteosarcoma cell lines with over expression of 
TRIB2 (U2OS-TRIB2) and endogenous TRIB2 
protein expression (U2OS-Empty). Cell lines were 
treated with 100nM of each indicated compound and 
50µg of total protein lysate was loaded per lane. β-
actin is shown to indicate protein loading. . 
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3.2- PI3K inhibition does not result in an increase in TRIB2 transcription 
We next questioned what the mechanism was for this increase in TRIB2 protein 
expression following PI3K inhibition. To answer this question, we treated cells with each 
of our novel PI3K inhibitors and 12 hours post exposure, collected total RNA (described 
in materials and 
methods). Once we 
had our RNA 
extracted, we 
generated cDNA and 
conducted 
quantitative real time 
PCR (qRT-PCR) 
analysis (Figure 
3.2.1).  Interestingly, 
we note that there 
was no significant increase in the level of TRIB2 transcription following PI3K treatment 
in either of our isogenic U2OS cell lines. As we would expect, our U2OS-TRIB2 cells 
show an almost 6 fold increase in TRIB2 expression compared to endogenous U2OS-
Empty cells. From this study, we can conclude that the increase we note in TRIB2 protein 
levels post-PI3K inhibition was independent of transcription. 
3.3- TRIB2 keeps mRNA and protein stability in the presence of PI3K inhibitors 
Having observed no significant difference in TRIB2 transcription following PI3K 
inhibition, we next questioned if the increase in TRIB2 protein levels after PI3K 
inhibition was the 
result of a change in 
mRNA stability. We 
conducted an 
actinomycin D (ActD) 
time course study 
following exposure to 
our PI3K inhibitors. 
Actinomycin D is a 
drug that binds to the 
Figure 3.2.1- PI3K inhibition does not change levels of TRIB2 expression 
qRT-PCR of our isogenic osteosarcoma cell lines following PI3K inhibitor 
exposure. TRIB2 transcription was evaluated and normalized to GAPDH 
using the 2-  methodology. N = 6. Statistical analysis was carried out using 
a 2-tailed analysis of variance (ANOVA) approach. 
Figure 3.3.1- PI3K inhibition does not alter TRIB2 mRNA synthesis 
Left) qRT-PCR of U2OS-TRIB2 cells treated with Actinomycin D and PI3K 
inhibitors. Right) qRT-PCR of U2OS-Empty cells treated with Actinomycin 
D and Pi3K inhibitors. TRIB2 transcription was evaluated and normalized to 
GAPDH using the 2-ΔΔCT methodology. N = 6. Statistical analysis was carried 
out using a 2-tailed analysis of variance (ANOVA) approach. 
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DNA and blocks RNA synthesis (61). Collecting total RNA from each isogenic cell line 
at 1hr, 3hr 6hr and 12 hr (Figure 3.3.1).  We generated cDNA from the total RNA at each 
time post ActD exposure and conducted qRT-PCR analysis.  It is important to note here 
that the time point indicated in each graph shown in Figure 3.3.1 is the time post ActD 
addition and that at the time point 0 hr, the cell lines have been incubated in the presence 
of each PI3K inhibitor for 3 hours. Consequently, when the 12 hour time point is reached 
(12 hours post ActD addition) the respective cell lines have been in the presence of each 
PI3K inhibitor for 15 hours. We saw no difference in the amounts of TRIB2 mRNA at 
each time point in the presence of each PI3K inhibitor and ActD indicating that there was 
no change in TRIB2 mRNA stability post PI3K inhibition.  
Having observed no significant difference between either TRIB2 transcription or 
TRIB2 mRNA stability, we questioned if the TRIB2 protein stability was effected 
following PI3K inhibition. Similarly to our ActD studies, we treated our isogenic cell line 
with each PI3K inhibitor in the presence of cycloheximide (CHX) (an inhibitor of protein 
synthesis) (62) (Figure 
3.3.2). It is important to 
note here that the time 
point indicated in each 
graph shown in Figure 
3.3.2 is the time post 
CHX addition and that 
at the time point 0 hr, the 
cell lines have been 
incubated in the presence 
of each PI3K inhibitor 
for 12 hours. 
Consequently, when the 
12 hour time point is reached (12 hours post CHX addition) the respective cell lines have 
been in the presence of each PI3K inhibitor for 24 hours. In the case of the 1 hour time 
point (this is 13 hours with each PI3K inhibitor), 3 hr (is 15 hours in the presence of the 
inhibitors) and 6 hr represents 18 hours in the presence of the PI3K inhibitors. In both 
U2OS-TRIB2 and U2OS-Empty cells, we note that there is a significantly higher amount 
of TRIB2 protein in the presence of each PI3K inhibitor tested.  
Figure 3.3.2- PI3K inhibition does not affect protein synthesis. 
Western blot quantification of U2OS-TRIB2 and U2OS-Empty cells 
incubated with cycloheximide (CHX) for the time points shown. At the 
time the CHX time course was initiated (0hr), the cells have already been 
incubated in the presence of each specific PI3K inhibitor for 12 hours. 
Left) U2OS-TRIB2 treated cells. Right) U2OS-empty treated cells. qRT-
PCR of U2OS-Empty cells treated with Actinomycin D and Pi3K 
inhibitors. TRIB2 protein levels were evaluated and normalized to β-actin 
(applying the 2-ΔΔCT normalization methodology). N = 3. 
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However, irrespective of the compound tested, there was no statistically significant 
difference in the gradient of each graph for total TRIB2 amount. Therefore, while there 
is a clear increase in the amount of total TRIB2 protein following incubation with each 
PI3K (independent of whether this was endogenous or exogenous TRIB2), there is no 
significant difference in TRIB2 protein stability post PI3K-inhibition. 
3.4- PI3K treatment significantly reduces proteasome-dependent degradation of 
TRIB2 
Having questioned if the increase in total TRIB2 protein was the result of a change 
in TRIB2 transcription, TRIB2 mRNA stability or TRIB2 protein stability, we investigated 
if there was a change in proteasome-
dependent degradation. We treated our 
isogenic cell lines with  MG132, a small 
peptide that acts as a proteasome inhibitor 
(63). We found that when incubated in the 
presence of MG132, there was no longer an 
increase in TRIB2 protein levels post PI3K 
inhibition (Figure 3.4.1).  
 
 
3.5- TRIB2 protein expression correlates with increased total AKT and 
significantly elevated pSer473-AKT. 
Previous data from our group indicated that in a range of isogenic cell lines and in 
vitro models that, in the presence of high TRIB2 protein, there is a significantly higher 
level of active pSer473-AKT (Figure 3.5.1; kindly provided by Dr Richard Hill).  
Figure 3.4.1– PI3K inhibition reduces TRIB2 
degradation 
Top) Western blot of U2OS-TRIB2 cells treated 
with each PI3K inhibitor in the absence/presence of 
per lane.  Bottom) Quantification of multiple (3) 
western blots for TRIB2 following PI3K incubation 
-/+ MG132. Statistical analysis was carried out using 
a 2-ΔΔCT methodology, normalized to β-actin. In the 
presence of MG132 we notice the accumulation of 2 
larger (higher) TRIB2 protein bands.   
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3.6- COP1 domain is the crucial region required for pSer473 AKT post-
translational modification 
Data (unpublished) from our group has revealed that the TRIB2 protein is capable 
to bind and activate AKT. However, the specific region of TRIB2 that is responsible for 
that action is unknown. To address this we used a range of mutant TRIB2 constructs 
(Figure 3.6.1). We transfected 2 µg of each plasmid into human 293T renal carcinoma 
cells. 24 hours post transfection we screened transfected cells by immunoblotting for 
pSer473-AKT, pSer253-FOXO3a, pSer166-MDM2 and GFP (Figure 3.6.2). Mutants that 
retained the COP1-binding domain showed phosphorylation of downstream members of 
the PI3K pathway.  We included GFP in this study as each construct was tagged with 
GFP. This served as a control for 
our studies as neither of our α-
TRIB2 antibodies (CNIO or Santa 
Cruz Biotechnology) would 
recognise all of these constructs 
(data not shown). 
Figure 3.5.12- TRIB2 protein expression 
correlates with pSer473-AKT.  
TRIB2 protein levels correlate with AKT-
Ser473 phosphorylation in a broad range of 
model in vitro models. Representative 
images showing 100 μg (TRIB2), 50 μg 
(AKT-Ser473) total protein loaded per lane 
separated by 10% SDS-PAGE. sc indicates 
scramble shRNA within the indicated cell 
lines. 
Figure 3.6.1- TRIB2 mutant constructs. Schematic figure of 
various TRIB2 mutant constructs used in our studies (kindly 
provided by Dr. Stephen Pear). 
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3.7- Low levels of FOXO3a-mediated genes transcription correlate with increased 
AKT activity  
To further analyse if the COP1 domain is in fact responsible for the activation of 
AKT, we studied the gene expression levels of target genes of FOXO3a. In particular, we 
focused on p27 and FasLG to attest how cell cycle arrest and apoptosis were affected 
following transient reinfection with each TRIB2 construct. As mentioned before, p27 is 
affected by the PI3K/AKT pathway because it needs FOXO3a to be expressed. AKT 
directs the post-translational modification of FOXO3a phosphorylating it at the Ser253 
residue following which, FOXO3a is trafficked out of the nucleus into the cytoplasm for 
polyubiquitination and degradation. Consequently, high levels of phosphorylated AKT 
are indicative of low levels of FOXO3a and by consequence, low levels of p27 (at both 
the transcript and protein level). The same “chain-of-events” applies to FasLG. These 
transfection studies indicated that TRIB2 proteins that contained the COP1 domain had 
low levels p27 and FasLG transcription (Figure 3.7.1, 3.7.2), supporting our immunoblot 
data where we note AKT and FOXO3a phosphorylation.      
 
Figure 3.6.2- TRIB2 acts through the 
COP1 domain. Western blot with 
HEK293T cell lines transfected with the 
mutant constructs. 50 µg of lysate used in 
each lane. 
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Figure 3.7.2- Low levels of FasLG gene expression in mutants still possessing the COP1-binding 
domain. qRT-PCR of HEK293T cell lines transfected with mutant constructs. 
Figure 3.7.1- Low levels of p27 gene expression in mutants still possessing the COP1-binding domain. 
qRT-PCR of HEK293T cell lines transfected with mutant constructs. 
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We next questioned if our transcription results for p27 and FasLG were conserved 
at the protein level (i.e. in TRIB2-mutant construct transfected cells if there was  p27 and 
FasLG protein induction following PI3K exposure). Following transient transfection of 
each construct and exposure to BEZ235 (a dual PI3K/mTOR inhibitor) we analysed by 
immunoblot, the protein levels of p27 and FasLG (Figure 3.7.3). The results correlate, 
with same mutants with low levels of gene expression showing low levels of protein 
expression of p27 and FasLG (Figure 3.7.3).   
 
These results also support our studies demonstrating that TRIB2 is actively 
involved in mechanisms of drug resistance in various cancers (metastatic melanoma, 
colon and pancreatic to name a few). Through the COP1-binding domain within the 
protein, TRIB2 is activating AKT and promoting cell survival by suppressing FOXO3a 
(directly) and p53 (indirectly). 
To further prove the role of TRIB2 in activating AKT and chemotherapeutic 
resistance, we used FACS scanning (described in materials and methods) of the 
transfected 293T cell line after treatment with each specific PI3K inhibitor. Following 
transient transfection and PI3K inhibitor exposure, we measured the percentage of SubG1 
cells in each population (i.e. the percentage of dead/non-viable cells). The results revealed 
that the cells transfected with the TRIB2 mutants containing the COP-1 binding domain 
were no longer more resistant to various novel PI3K inhibitors and that they displayed 
significant increases in the percentage of SubG1 cells (Figure 3.7.4).  
Figure 3.7.3- Low levels of protein expression of p27 and FasLG in mutant constructs still possessing 
the COP1-binding domain. Left) Western blot of U2OS-TRIB2 cells treated with PI3K inhibitor BEZ235. 
50 µg of total protein lysate was loaded per lane. Right) Quantification of multiple (3) western blots for 
TRIB2 following PI3K inhibition. Statistical analysis was carried out using a 2-ΔΔCT methodology, 
normalized to β-actin. 
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The previous studies were obtained in transient transfected 293T cells with a mixed 
population. As a result, we hypothesised that there would be cells within this mixed 
population with high plasmid expression and those which did not take up the plasmid. 
Each construct was tagged with GFP so we asked if we could FACS sort the transfected 
cells following BEZ235 treatment into GFP positive and GFP negative. Upon obtaining 
the two populations, we 
extracted the proteins and with 
these sorted populations, we 
analysed the levels of protein 
expression of p27 (Figure 3.7.5) 
and BIM (Figure 3.7.6). 
Strikingly, our FAC-
sorting data correlated with our 
previous findings and that GFP 
positive cells from the FL, ΔN 
and CTerm constructs could not 
Figure 3.7.4- Cells with TRIB2 mutants possessing COP1-binding domain can transition the G1 
checkpoint. 10,000 total events were scored per study. Data was analysed using Infinicyt (Cytognos). 
 
Figure 3.7.5-Protein expression of p27 in GFP+ and GFP- 
populations. Representative immunoblot image for p27 or β-
actin following FAC-sorting post transient transfection and 100 
nM BEZ235 treatment. Cell populations were sorted using our 
FACS-Aria II sorter and the total protein extracted from each 
population. 50 μg total protein lysate was run on 10% SDS-PAGE 
gels and probed for p27 or β-actin (n=2).  
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repress p27 or BIM expression but that within these sorted populations, the GFP negative 
population lost this ability. Irrespective of GFP status, the other constructs could not 
repress p27 or BIM induction.   An important caveat of this study was that each study 
required the transient transfection of individual constructs in different passages of 293T 
cells. Consequently, the transfection efficiency could vary. In addition, we only sorted 
cells that had an extremely high GFP signal. Consequently, within each mixed population, 
there were cells with low GFP signals that could have been incorporated/sorted within 
the GFP negative pool. This could account for the repression profile that while attenuated, 
can still be observed (somewhat) in our samples evaluated for BIM (Figure 3.7.6). As 
such, these studies need to be expanded and repeated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7.6- Protein expression of 
BIM in GFP+ and GFP- populations.   
Representative immunoblot image for 
BIM or β-actin following FAC-sorting 
post transient transfection and 100 nM 
BEZ235 treatment. Cell populations 
were sorted using our FACS-Aria II 
sorter and the total protein extracted 
from each population. 50 μg total 
protein lysate was run on 10% SDS-
PAGE gels and probed for p27 or β-
actin (n=2).  
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4. Conclusion 
 
TRIB2 has been established as a FOXO repressor protein with oncogenic capacity 
in melanoma. Previous work from our group has found that TRIB2 is a melanoma 
biomarker for diagnosis, progression and patient response to conventional first line 
chemotherapy. This capacity arises from its ability to interact with the PI3K/AKT 
pathway, a key signalling pathway for cell survival. Intriguingly, the TRIB2 protein levels 
have been found to be increased upon treatment with PI3K inhibitors. The present study 
reveals that TRIB2 protein levels increase post PI3K inhibition due to a decrease in 
proteasomal degradation. Proteasomal degradation is a mechanism for cells to get rid of 
unnecessary or damaged proteins, keeping homeostasis. For degradation to be initiated, 
the target proteins must be “tagged” through post-translational modifications such as 
ubiquitination (64).  
Our results imply that the degradation of TRIB2 is regulated by the PI3K pathway. 
When PI3K inhibitors block the activation of the pathway, they appear to be affecting the 
“tagging” of TRIB2 for degradation. As such, we hypothesise that a downstream target 
that is activated upon PI3K/AKT signalling is responsible for the post-translational 
modification that “tags” TRIB2 for proteasomal degradation. Obvious candidates include 
MDM2 (Hill and Link, unpublished data) and COP1 (55), both E3 ubiquitin ligases that 
interact with TRIB2. MDM2 is also a known target of AKT. These E3 ubiquitin ligases 
may be responsible for the ubiquitination of TRIB2. However, the precise underlying 
mechanism remains to be determined. A recent study reports other candidates responsible 
for the degradation of TRIB2 (65). The authors show that p70S6K can phosphorylate 
TRIB2, inducing the SMAD ubiquitination regulatory factor 1 (Smurf1) to 
polyubiquitinate TRIB2 (65). They also showed that impairing any of these modifications 
stabilizes TRIB2 and enhances its carcinogenic properties in liver cancer cells (65). These 
data are very intriguing as p70S6K can be activated by PI3K/AKT signalling. Therefore 
we hypothesise that the inhibition of PI3K might reduce MDM2 or Smurf1 activity and 
in turn decrease proteasomal degradation of TRIB2. 
These are extremely relevant observations for cancer treatment, specifically for 
drug resistance. In clinical practice, patients with tumours that overexpress TRIB2 will 
have an intrinsic resistance to the use of PI3K inhibitors. Furthermore, patients with lower 
levels of TRIB2, if treated with PI3K inhibitors, might acquire resistance through the 
stabilization of TRIB2 protein levels.  
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Further studies will be required to establish the underlying mechanism of TRIB2 
degradation and how it affects cancer chemotherapies. 
The present work also shows that TRIB2 is able to bind and activate AKT and that 
this interaction is mediated by its COP1-binding domain. AKT is activated by 
phosphorylation on two different residues, Threonine 308 and Serine 473. As shown here 
TRIB2 expression increases phosphorylation of Ser473, a residue known to be 
phosphorylated by the mTORC2 complex. There is very recent evidence in our lab that 
TRIB2 does not affect the PDK-1 mediated phosphorylation of Thr308 (currently under 
review). This data suggests that TRIB2 functions as an adaptor protein that facilitates the 
phosphorylation of the Serine 473. We hypothesise that TRIB2 binds to AKT and recruits 
mTORC2, which is known to phosphorylate the Ser473 residue. Another interesting 
possibility emerges from a recent study by Velasco et al. on the role ofTRIB3 in cancer. 
This group shows that TRIB3 possesses a tumour inhibitory role through the regulation 
of the activity of the AKT pathway in breast cancer cells (66). They also show that 
inhibition of TRIB3 increases tumorigenesis due to enhanced phosphorylation of AKT 
by the mTORC2 complex and subsequent inactivation of FOXO3 (66). Their results and 
our data suggest that TRIB2 and TRIB3 may compete for AKT binding, with opposing 
functions. 
Another recent seminal work showed that TRIB2 can bind to ATP and 
autophosphorylate in a metal-independent manner (67) suggesting that TRIB2 could act 
as a kinase. They proved in vitro that ATP binds with low affinity to the Lys90 residue 
of the catalytic site of TRIB2. They also show that targeting that site with small molecules 
may be a viable pursuit for development of novel chemotherapeutics (67). 
 
4.1- Future Directions 
The findings presented in this study provide the groundwork for future basic and 
translational research. The mechanism of by which TRIB2 protein levels are regulated, 
in particular the identification of the molecular mechanism of its proteasomal degradation 
and the involved players would shed light on the influence of PI3K/AKT signalling on 
this process. As mentioned above this could be a mechanism for both acquired and 
intrinsic resistance against anti-cancer drugs that interfere with the PI3K/AKT signalling 
network. Expanding our studies to in vivo or clinical samples could establish TRIB2 as a 
predictive biomarker capable of stratifying cancer patients into responders and non-
responders to these agents. The result showing the interaction of TRIB2 and AKT via its 
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COP1 domain suggests several testable hypotheses, including the competition of TRIB2 
and TRIB3 for AKT binding or the direct recruitment of the mTORC2 complex by 
TRIB2/AKT. A further understanding of the exact mechanism how TRIB2 activates AKT 
is of key importance for the development of therapies aimed at interfering with the 
activation of AKT and to overcome TRIB2 mediated drug resistance. 
This work only tested for a few downstream targets of the FOXO and p53 
transcription factors. These factors are known to regulate the transcription of a vast array 
of genes. As predicted, our results of ChIP assays showed a suppression of FOXO3a and 
p53 target gene expression upon increased TRIB2 levels. These data was not presented 
in this work for they were preliminary results and further experiments are required. The 
identification of targets that are critically involved in TRIB2 mediated drug resistance 
would further increase the mechanistic insight into this clinically relevant process. 
 
      
    
 
 
.  
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Figure A.1: Datasheet of phospho-AKT antibody (hhttp://www.scbt.com/) 
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Figure A.2: Datasheet of Total AKT antibody (hhttp://www.scbt.com/) 
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Figure A.3: Datasheet of Total FOXO antibody (hhttp://www.scbt.com/) 
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Figure A.4: Datasheet of Actin antibody (hhttp://www.scbt.com/) 
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Figure A.5: Datasheet of MDM2 antibody (hhttp://www.scbt.com/) 
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Figure A.6: Datasheet of BIM antibody (hhttp://www.scbt.com/) 
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Figure A.7: Datasheet of FasLG antibody (hhttp://www.scbt.com/) 
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Figure A.8: Datasheet of p27 antibody (hhttp://www.scbt.com/) 
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Figure A.9: Datasheet of phospho-FOXO antibody (hhttp://www.scbt.com/) 
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Figure A.10: Datasheet of Lamin antibody (hhttp://www.scbt.com/) 
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Figure A.11: Datasheet of phospho-MDM2 antibody (hhttp://www.cellsignal.com/) 
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Figure A.12: Datasheet of goat anti-rabbit secondary antibody (hhttp://www.scbt.com/) 
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Figure A.13: Datasheet of donkey anti-goat secondary antibody 
(hhttp://www.scbt.com/) 
 
57 
 
 
 
 
 
Figure A.14: Datasheet of goat anti-mouse secondary antibody 
(hhttp://www.scbt.com/) 
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Figure A.15: Datasheet of anti-mouse secondary antibody (http://www. 
sigmaaldrich.com/) 
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Figure B.1: jetPRIME Transfection Kit Protocol 
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Figure B.2: jetPRIME Transfection Kit Protocol 
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Figure C.1: Tri-Reagent Protocol (http://www. sigmaaldrich.com/) 
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Figure C.2: Tri-Reagent Protocol (http://www. sigmaaldrich.com/) 
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Figure C.3: Tri-Reagent Protocol (http://www. sigmaaldrich.com/) 
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Figure C.4: Tri-Reagent Protocol (http://www. sigmaaldrich.com/) 
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Figure C.5: Tri-Reagent Protocol (http://www. sigmaaldrich.com/) 
 
66 
 
 
 
Figure D.1: NzyGelpure protocol (https://www.nzytech.com/) 
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Figure D.2: NzyGelpure protocol (https://www.nzytech.com/) 
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Figure D.3: NzyGelpure protocol (https://www.nzytech.com/) 
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Figure D.4: NzyGelpure protocol (https://www.nzytech.com/) 
 
70 
 
 
 
Figure E.1: Nzy First-Strand cDNA Synthesis Kit protocol (https://www.nzytech.com/) 
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Figure E.2: Nzy First-Strand cDNA Synthesis Kit protocol (https://www.nzytech.com/) 
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Figure F.1: LuminoCt SYBR Green qPCR ready mix Protocol (http://www. 
sigmaaldrich.com/) 
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Figure F.2: LuminoCt SYBR Green qPCR ready mix Protocol (http://www. 
sigmaaldrich.com/) 
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Figure F.3: LuminoCt SYBR Green qPCR ready mix Protocol (http://www. 
sigmaaldrich.com/) 
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Figure F.4: LuminoCt SYBR Green qPCR ready mix Protocol (http://www. 
sigmaaldrich.com/) 
 
